Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Two Patents, Five Patent Applications Related to RNAi

Title: Inhibitors of Ribonucleotide Reductase Subunit 2 and Uses Thereof
Number: 7,427,605
Filed: March 31, 2006
Lead Inventor: Mark Davis, Calando Pharmaceuticals
The patent, its abstract states, “relates to inhibitors of ribonucleotide reductase subunit 2, and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs.”

Title: High-Throughput Methods for Identifying Gene Function Using Lentiviral Vectors
Number: 7,427,474
Filed: July 25, 2003
Inventor: Boro Dropulic, Virxsys
The invention, the patent abstract states, “relates to methods and compositions for the efficient identification of one or more functionalities of a product encoded by a nucleic acid sequence of interest. The methods utilize the abilities to over- and/or under-express the product in a cell, as well as the combination of these results, to permit the identification of at least one of the product's cellular or in vivo functionality.”

Title: siRNA Targeting Ribonucleotide Reductase M2 Polypeptide
Number: 20080227967
Filed: June 13, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to RRM2.”

Title: Cell-Based RNA Interference and Related Methods and Compositions
Number: 20080226553
Filed: Sept. 29, 2003 PCT Filed: Sept. 29, 2003
Lead Inventor: Scott Lowe, Cold Spring Harbor Laboratory
The invention claims, among other things, “methods for performing RNA interference in stem cells and methods for using stem cells in vivo,” the patent application’s abstract states.

Title: Method for Identification of Polynucleotides Capable of Cleaving Target mRNA Sequences
Number: 20080227103
Filed: Feb. 19, 2008
Lead Inventor: John Sullivan, University at Buffalo, State University of New York
According to the patent application’s abstract, the invention comprises “methods for identifying a polynucleotide that can reduce the level of a target mRNA. The method can be performed by providing cells that express an RNA polynucleotide that contains a target mRNA sequence, an internal ribosome entry sequence, and a sequence encoding a secreted reporter protein; introducing to the cells a test polynucleotide, and measuring activity of the secreted reporter protein.”
The abstract adds that “a reduction in secreted reporter protein activity relative to a control cell into which the test polynucleotide has not been introduced is indicative that the test polynucleotide is capable of reducing the level of the target mRNA in the cells. The method is adaptable for high-throughput screening methods and is suited for identifying polynucleotides that can catalyze cleavage of target mRNA and/or act on target mRNA through and antisense or RNAi mechanism.”

Title: Method for Treating and Preventing Ischemia Reperfusion Injury Using RNA Interfering Agent
Number: 20080227733
Filed: Nov. 1, 2004 PCT Filed: Nov. 1, 2004
Lead Inventor: Judy Lieberman, Immune Disease Institute (Harvard University)
The invention, the patent application’s abstract states, is based, at least in part, “on the discovery of methods useful in the modulation … of gene expression or protein activity. … In particular, the … invention is based on novel RNA interfering agents [capable of reducing] apoptosis-related gene expression or cytokine expression in cells. Inhibition of apoptosis-related gene expression or protein activity or cytokine gene expression or protein activity … inhibits ischemia-reperfusion injury.”

Title: Recombinant DNA Constructs and Methods for Controlling Gene Expression
Number: 20080229456
Filed: Oct. 10, 2006
Lead Inventor: Shihshieh Huang, Monsanto
The invention, the patent application’s abstract states, “provides molecular constructs … including constructs including heterologous miRNA recognition sites; constructs for gene suppression including a gene-suppression element embedded within an intron flanked on one or on both sides by non-protein-coding sequence; constructs containing engineered miRNA or miRNA precursors; and constructs for [suppressing] production of mature microRNA in a cell. Also provided are transgenic plant cells, plants, and seeds containing such constructs, and methods for their use.”
The abstract adds that the invention “further provides transgenic plant cells, plants, and seeds containing recombinant DNA for the ligand-controlled expression of a target sequence, which may be endogenous or exogenous. Also disclosed are novel miRNAs and miRNA precursors from crop plants including maize and soy.”

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.